A small NYC-led cancer trial has achieved a result reportedly never before seen – the total remission of cancer in all of its patients, reported NBC New York. Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before.
The New York time reported that in a small trail with just eighteen rectal cancer patients were given the drug and the results were astonishing as cancer had vanished in every single patient given the same drug and the cancer was undetectable after physical exam, endoscopy, PET scans or M.R.I. scans.
Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by the drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient, NYT reported.
“I believe this is the first time this has happened in the history of cancer,” Dr. Diaz said.
Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, said he also thought this was a first. A complete remission in every single patient is “unheard-of,” he said.
